Showing 17–32 of 71 resultsSorted by popularity
Anastrozole (Arimidex) is a benzyltriazole-derived Type II non-steroidal aromatase inhibitor that competitively binds the heme group of CYP19A1, blocking androgen-to-estrogen conversion. A reversible, high-fidelity tool for precise estrogen modulation research.
Superdrol (Methasterone) is a highly potent C17-alpha-alkylated DHT derivative featuring a 2-alpha methyl group that prevents aromatization while maximizing anabolic potency. It delivers exceptional myofibrillar protein transcription with no estrogenic conversion.
Semaglutide is a long-acting GLP-1 receptor agonist with a 168-hour half-life that stimulates glucose-dependent insulin secretion and centrally suppresses appetite. An oral formulation for investigating sustained incretin-mediated weight loss.
Finasteride is a selective Type II 5-alpha-reductase inhibitor that competitively blocks testosterone-to-DHT conversion, reducing serum DHT by approximately 70%. A targeted research tool for investigating androgen-dependent hair follicle preservation.
Dianabol (Methandienone) is a potent C17-alpha-alkylated testosterone derivative featuring a delta-1 double bond for enhanced anabolic activity. It drives rapid myofibrillar protein synthesis and positive nitrogen balance, rendering it a core oral androgen for muscle growth research.
SLU-PP-332 is a first-in-class pan-agonist of Estrogen-Related Receptors (alpha, beta, gamma) that recruits PGC-1alpha to upregulate mitochondrial oxidative phosphorylation. An oral exercise mimetic for investigating metabolic adaptation without physical exertion.
GW-501516 (Cardarine) is a high-affinity PPAR-delta agonist that recruits PGC-1alpha co-activators to upregulate fatty acid oxidation, mitochondrial biogenesis, and Type I oxidative fiber conversion. An excellent endurance-enhancing research compound.
Anadrol (Oxymetholone) is a potent C17-alpha-alkylated DHT derivative that uniquely stimulates erythropoietin secretion alongside androgen receptor activation, driving both red blood cell expansion and myofibrillar protein synthesis.
DHT-derived androgen for SHBG modulation and lean mass research. Study vascularity and fat loss pathways.
BPC-157 is a stable gastric pentadecapeptide that stimulates VEGFR2 expression and NO-mediated vasodilation for enhanced angiogenesis and tissue repair. An oral formulation for investigating gut-brain axis modulation and systemic healing.
Tesofensine is a potent triple monoamine reuptake inhibitor that simultaneously blocks presynaptic transporters for dopamine, norepinephrine, and serotonin, elevating synaptic neurotransmitter concentrations. A top-tier research tool for investigating appetite suppression and energy expenditure.
MK-677 (Ibutamoren) is a potent non-peptide ghrelin receptor agonist that stimulates endogenous pulsatile GH release from the pituitary without desensitization. It also elevates IGF-1 levels for full-scale somatotropic axis activation.
Winstrol (Stanozolol) is a C17-alpha-alkylated DHT derivative with a pyrazole ring modification that significantly reduces SHBG levels and inhibits glucocorticoid receptors. Its 9-hour half-life supports research into lean muscle hardening and strength enhancement without aromatization.
ERR pan-agonist for metabolic research at 1000mcg dosage. Investigate ERRalpha/beta/gamma activation and mitochondrial function.
Methylstenbolone is a potent C17-alpha-alkylated androgen with a 9-12 hour half-life that drives rapid myofibrillar protein transcription and positive nitrogen balance. Its unique structure provides strong anabolic signaling without aromatization.
MK-2866 (Ostarine) is a non-steroidal SARM that selectively agonizes androgen receptors in muscle and bone tissue with a Ki of 3.8 nM. Its 24-hour half-life provides steady receptor occupancy for investigating lean tissue preservation and muscle wasting prevention.
End of content
End of content
No products in the cart.
